orforglipron · Foundayo

Small molecule

Also known as LY3502970

Approvedregulatory verdict

Evidence outlook

Approved: Obesity

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

track record: Reliable signal

Also in development:Hypertension · Phase 3 · investigational in the USType 2 Diabetes · Phase 3 · investigational in the USAtherosclerotic Cardiovascular Disease · Phase 3 · investigational in the USOsteoarthritis · Phase 3 · investigational in the US

Also approved (1)
UK
  • Weight management in adults (BMI >=30, or 27-30 with a weight-related comorbidity) and glycaemic control in insufficiently controlled type 2 diabetes
Product first approved 2026MHRA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (27)
Atherosclerotic Cardiovascular Disease
Hypertension
NCT07794579 · Eli Lilly and Company
2026-08-26 – 2030-09 · Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
What this study did
NCT06948422 · Eli Lilly and Company
2025-04-30 – 2027-09 · Hypertension
What this study did
NCT06952530 · Eli Lilly and Company
2025-04-30 – 2027-09 · Hypertension
What this study did
Obesity
NCT06672939 · Eli Lilly and Company
2024-11-18 – 2031-01 · Obesity, Overweight
What this study did
NCT07790861 · Eli Lilly and Company
2026-12 – 2028-03 · Obesity, Overweight
What this study did
NCT07202884 · Eli Lilly and Company
2025-09-30 – 2028-03 · Urinary Incontinence,Stress
What this study did
NCT06972459 · Eli Lilly and Company
2025-05-15 – 2027-08 · Obesity, Overweight
What this study did
NCT06672549 · Eli Lilly and Company
2024-11-18 – 2027-03 · Obesity, Overweight
What this study did
NCT06649045 · Eli Lilly and Company
2024-10-22 – 2026-07-30 · OSA, Overweight or Obesity
What this study did
NCT05931380 · Eli Lilly and Company
2023-07-31 – 2025-06-19 · Obesity
What this study did
Osteoarthritis
Type 2 Diabetes
NCT07668336 · Eli Lilly and Company
2026-07-08 – 2030-03 · Diabetes Mellitus, Type 2
What this study did
NCT06972472 · Eli Lilly and Company
2025-05-19 – 2027-08 · Obesity, Overweight, Type 2 Diabetes
What this study did
NCT06993792 · Eli Lilly and Company
2025-05-15 – 2027-08 · Obesity, Overweight, Type 2 Diabetes
What this study did
NCT07613307 · Eli Lilly and Company
2026-07-15 – 2027-05 · Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases, Endocrine System Diseases, Feeding Behavior, Behavior, Fasting, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide Receptors, Receptors, G-Protein-Coupled, Receptors, Cell Surface, Membrane Proteins, Proteins, Receptors, Peptide
What this study did
NCT06045221 · Eli Lilly and Company
2023-09-22 – 2025-08-22 · Type 2 Diabetes
What this study did
NCT06010004 · Eli Lilly and Company
2023-09-28 – 2025-06-05 · Type 2 Diabetes
What this study did
NCT05971940 · Eli Lilly and Company
2023-08-09 – 2025-04-03 · Type 2 Diabetes
What this study did
Phase 2 (2)
Obesity
NCT05051579 · Eli Lilly and Company
2021-09-29 – 2022-11-22 · Obesity, Overweight and Obesity
What this study did
Type 2 Diabetes
NCT05048719 · Eli Lilly and Company
2021-09-15 – 2022-09-30 · Type 2 Diabetes
What this study did
Phase 1 (21)
Obesity
NCT06824051 · Eli Lilly and Company
2025-02-17 – 2026-01-26 · Obesity, Overweight
What this study did
NCT06440980 · Eli Lilly and Company
2024-06-24 – 2025-06-02 · Healthy, Obese, Overweight, Obesity
What this study did
NCT06023095 · Eli Lilly and Company
2023-09-21 – 2024-07-29 · Overweight, Obesity
What this study did
NCT06186622 · Eli Lilly and Company
2024-01-02 – 2024-07-10 · Healthy, Obese, Overweight
What this study did
NCT05841238 · Eli Lilly and Company
2023-04-26 – 2023-11-13 · Healthy, Obese
What this study did
NCT05313802 · Eli Lilly and Company
2022-05-26 – 2022-09-09 · Healthy, Obese
What this study did
Type 2 Diabetes
NCT05086445 · Eli Lilly and Company
2021-11-12 – 2022-09-05 · Diabetes Mellitus, Type 2
What this study did
NCT04426474 · Eli Lilly and Company
2020-10-08 – 2021-07-12 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT06692348 · Eli Lilly and Company
2024-12-13 – 2025-06-09 · Healthy
What this study did
NCT06704763 · Eli Lilly and Company
2024-12-06 – 2025-02-05 · Healthy
What this study did
NCT05882032 · Eli Lilly and Company
2023-06-13 – 2024-11-18 · Healthy, Hepatic Insufficiency
What this study did
NCT06370728 · Eli Lilly and Company
2024-05-06 – 2024-07-23 · Healthy
What this study did
NCT05936138 · Eli Lilly and Company
2023-07-13 – 2024-04-11 · Renal Insufficiency, Healthy
What this study did
NCT06085482 · Eli Lilly and Company
2023-10-19 – 2024-01-05 · Healthy
What this study did
NCT05573230 · Eli Lilly and Company
2022-10-17 – 2023-01-17 · Healthy
What this study did
NCT05469126 · Eli Lilly and Company
2022-08-01 – 2022-11-03 · Healthy
What this study did
NCT05341089 · Eli Lilly and Company
2022-05-17 – 2022-09-01 · Healthy
What this study did
NCT05051566 · Eli Lilly and Company
2021-09-16 – 2022-04-04 · Healthy
What this study did
NCT05110794 · Eli Lilly and Company
2021-11-05 – 2022-02-10 · Healthy
What this study did
NCT04680767 · Eli Lilly and Company
2021-03-29 – 2021-07-03 · Healthy
What this study did
NCT03929744 · Eli Lilly and Company
2019-06-12 – 2020-11-02 · Healthy
What this study did
Phase 4 (2)
Obesity
NCT07729332 · Massachusetts General Hospital
2026-11-01 – 2031-07-31 · Obesity
What this study did
Type 2 Diabetes
NCT07739537 · Massachusetts General Hospital
2026-10-01 – 2030-09-30 · Diabete Type 2, Pharmacogenomic Drug Interaction
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Obesity
NCT07793019 · Innovent Biologics (Suzhou) Co. Ltd.
2026-09-07 – 2028-01-26 · Overweight, Healthy Participants, Obesity
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Obesity: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Orforglipron (Foundayo): this drugApprovedSmall moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Liraglutide (Saxenda)ApprovedPeptideGLP-1 receptorReliable signal
NCT02918279: Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54)
NCT01557166: Change From Baseline in Apnoea-hypopnoea Index (AHI) (Week 0, Week 32): Liraglutide 3.0 mg -12.22 events/hour (Standard Deviation 23.34) vs Placebo -6.08 events/hour (Standard Deviation 25.9)
Naltrexone / Bupropion (Contrave)ApprovedSmall moleculeOpioid receptor / dopamine (combination), Dopamine/norepinephrine transporternot yet graded
NCT03374956: Change in Total Body Weight (baseline to 12 weeks): Intervention Group -7.7% (IQR -11 to -4.7) vs Control Group -6.5% (IQR -11 to -2.3) phase 3 result · pivotal pending
Orlistat (Xenical)ApprovedSmall moleculePancreatic/gastric lipaseWeak signalNo reviewed efficacy summary in this indication
Phentermine / Topiramate (Qsymia)ApprovedSmall moleculeNoradrenergic/anticonvulsant (combination)Reliable signal
NCT00553787: Percent Weight Loss From Baseline to Week 56 (Baseline to 56 weeks): VI-0521 Mid 7.81% (Standard Error 0.365) | VI-0521 Top 9.84% (Standard Error 0.275) vs Placebo 1.24% (Standard Error 0.277)
NCT00554216: Percent Weight Loss From Baseline to Week 56 (baseline to 56 weeks): VI-0521 Low 5.1% (Standard Error 0.538) | VI-0521 Top 10.92% (Standard Error 0.392) vs Placebo 1.55% (Standard Error 0.395)
Semaglutide (Wegovy Tablets)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
NCT03548935: Change in Body Weight (%) (Baseline (week 0) to week 68): Semaglutide 2.4 mg — In-trial observation period: -15.6% (Standard Deviation 10.1); On-treatment observation period: -16.9% (Standard Deviation 9.4) vs Placebo — In-trial observation period: -2.8% (Standard Deviation 6.5); On-treatment observation period: -3.1% (Standard Deviation 6.4)
Setmelanotide (Imcivree)ApprovedPeptideMC4RWeak signal
NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984)
NCT03287960: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88)
Tirzepatide (Zepbound)ApprovedPeptideGLP-1/GIP receptor (dual)Reliable signal
NCT05412004: Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21)
NCT04660643: Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53)
AleniglipronPhase 3Small moleculeGLP-1 receptorPartial signal
NCT06703021: Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001)
ASC30Phase 3Small moleculeGLP-1 receptorPartial signal
NCT07002905: Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06712836: Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results).
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06973681: Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity)
BofanglutidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT03856047: Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2)
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT05813925: Change in body weight at week 68: -18.4% (SE 0.7) CagriSema vs -11.9% (SE 0.7) semaglutide alone; ETD -6.5 percentage points (95% CI -8.4 to -4.6; p<0.0001)
DA-302168SPhase 3Small moleculeGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT05813795: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met.
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT05997576: Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025).
EfpeglenatidePhase 3PeptideGLP-1 receptorReliable signal
NCT06174779: Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signalNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptorReliable signal
NCT06230523: Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%.
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)Reliable signal
NCT06525935: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001)
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
LenbelintidePhase 3PeptideAmylin receptorPartial signalNo reviewed efficacy summary in this indication
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signal
NCT05669599: Primary endpoint percent change in body weight baseline to week 52 (treatment policy estimand): -12.3% to -16.2% across doses vs -2.5% placebo (obesity cohort); -8.4% to -12.3% vs -1.7% placebo (obesity-diabetes cohort)
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05607680: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met.
MDR-001Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
MibavademabPhase 3Monoclonal antibodyLeptin receptorPartial signalNo reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06839664: Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo.
PetrelintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signal
NCT06662539: Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05).
RAY1225Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT05931367: Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06396429: Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorReliable signal
NCT06904105: Percent body-weight change at week 44, treatment-policy estimand (prespecified primary): -8.0% (120 mg) and -9.8% (180 mg) vs -2.4% placebo, superiority stated as met (no p-value given). Proportion with at least 5% weight loss at week 44 (registry primary): 58.6% (120 mg) and 68.2% (180 mg); placebo rate and significance not reported.
SurvodutidePhase 3PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT06066515: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo).
NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo).
TesofensinePhase 3Small moleculeNoradrenaline/dopamine/serotonin reuptakeReliable signal
NCT00394667: After 24 weeks, mean weight loss with diet and placebo was 2.0%, while tesofensine doses produced significantly greater reductions of 4.5%, 9.2% and 10.6% respectively.
UBT251Phase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06939296: Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18).
NCT07011797: Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding.
VK2735Phase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06828055: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001
ZenagamtidePhase 3PeptideGLP-1/amylin receptor (dual)Weak signal
NCT06064006: Primary outcome, safety (number of treatment-emergent adverse events; no formal efficacy test). Secondary endpoint, estimated mean bodyweight change vs placebo: -24.3% vs -1.1% at week 36 (60 mg), -22.0% vs 1.9% (20 mg, week 36), -16.2% vs 2.3% (5 mg, week 28), -9.7% vs 2.0% (1.25 mg, week 20); p<0.0001 (Parts A-D), p=0.0003 (Part E) (Lancet 2025).
ZovaglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT07020884: Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001.
Efsubaglutide AlfaPhase 2/3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06732960: Efsubaglutide Alfa produced a mean weight reduction of 7.16% (95% CI: -8.08 to -6.24) versus 0.86% with placebo. Overall, 82.5% of Efsubaglutide-treated participants achieved >=5% weight loss (vs. 0% placebo).
ABBV-295Phase 2PeptideAmylin receptorWeak signalFeatured results are safety only in this race
Apitegromab (Isembyld)Phase 2Monoclonal antibodyMyostatin (pro/latent form)Partial signal
NCT06445075: Change from baseline in total Lean Body Mass at 24 weeks: -1.6 kg (-3.4 lbs) with apitegromab+tirzepatide vs -3.5 kg (-7.6 lbs) with placebo+tirzepatide; difference 1.9 kg (4.2 lbs) less lean-mass loss with apitegromab, i.e. 54.9% relative preservation (p=0.001).
ARD-101Phase 2Small moleculeBitter taste receptor (gut)Partial signal
NCT05121441: General-obesity Phase 2 (n=20): ARD-101 produced a 2.51-fold greater reduction in hunger rating (Control of Eating Questionnaire) vs placebo; p=0.015
AT-7687Phase 2PeptideGIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
AZD9550Phase 2PeptideGLP-1/glucagon receptor (dual)Partial signalNo reviewed efficacy summary in this indication
BGM1812Phase 2PeptideAmylin/calcitonin receptor (dual)Weak signal
NCT07224399: Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026)
BI 3034701Phase 2PeptideGLP-1/GIP/NPY2 receptor (triple)Weak signalNo reviewed efficacy summary in this indication
BimagrumabPhase 2Monoclonal antibodyActivin/myostatin type II receptorPartial signal
NCT05616013: Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17)
Bremelanotide (Vyleesi)Phase 2PeptideMC4RReliable signal
NCT06565611: BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001.
DapiglutidePhase 2PeptideGLP-1/GLP-2 receptor (dual)Partial signal
NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed
ECC4703Phase 2—Thyroid hormone receptor beta (THRβ)not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)Phase 2PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EnobosarmPhase 2Small moleculeAndrogen receptor (selective)Partial signal
NCT06282458: Change in total lean body mass at 16 weeks (day 112), enobosarm+semaglutide vs placebo+semaglutide: 71% relative reduction in lean mass loss (p=0.002); 27% greater fat loss vs control
ERX1000Phase 2Small moleculeLeptinWeak signalNo reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Garetosmab (Pasatru)Phase 2Monoclonal antibodyActivin Anot yet gradedNo reviewed efficacy summary in this indication
HM15275Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
HRS-4729Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
LAE102Phase 2Monoclonal antibodyActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
MacupatidePhase 2PeptideGIP receptornot yet gradedNo reviewed efficacy summary in this indication
Metreleptin (Myalept)Phase 2Protein / enzyme therapeuticLeptinPartial signalNo reviewed efficacy summary in this indication
NA-931Phase 2PeptideGLP-1/GIP/glucagon/IGF-1 receptors (quadruple)Partial signal
NCT06564753: Mean body weight reduction from baseline at Week 13: up to 13.8% at the 150 mg daily dose; 11.9% relative to placebo
NimacimabPhase 2Monoclonal antibodyCB1 receptornot yet gradedNo reviewed efficacy summary in this indication
NNC0519-0130Phase 2PeptideGLP-1/GIP receptor (dual)Partial signalNo reviewed efficacy summary in this indication
NNC0662-0419Phase 2PeptideGLP-1 / GIP / Amylin receptorsWeak signalNo reviewed efficacy summary in this indication
Orlistat / Acarbose (EMP16)Phase 2Small moleculeGI lipase + intestinal alpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
ParunoflastPhase 2Small moleculeNLRP3 inflammasome, NLRP3Weak signalFeatured results are safety only in this race
PG-102Phase 2Protein / enzyme therapeuticGLP-1/GLP-2 receptor (dual)Partial signalFeatured results are safety only in this race
Regor GLP-1Phase 2Small moleculeGLP-1 receptorPartial signal
NCT06277934: Safety (this trial's registered primary endpoint): AE-related discontinuation 4%, identical in drug and placebo arms; no treatment-related severe/serious AEs; nausea in 40% and vomiting in 24% of the RGT-075 arm; 1 patient (2%) required dose reduction.
RuvonoflastPhase 2Small moleculeNLRP3 inflammasomePartial signal
NCT07055516: Primary endpoint met: change from baseline in hsCRP up to week 24; effect sizes not yet given (RESOLVE-1, 2026-09-09).
NCT06129409: Phase Ib/IIa trial in 67 obese subjects with elevated CV risk/CRP, 28-day in-clinic dosing. >75% of NT-0796-dosed subjects reached hsCRP ≤2mg/L at day 28 vs <25% of placebo subjects; primary endpoint (hsCRP reduction) met with high statistical significance.
Taldefgrobep AlfaPhase 2Antibody-derived scaffoldActivin/myostatin type II receptornot yet gradedNo reviewed efficacy summary in this indication
TE-8105Phase 2PeptideGLP-1 receptorWeak signal
NCT06471530: Safety/tolerability (primary): <20% of participants had mild-to-moderate GI symptoms, no severe adverse events. Weight loss: 5 of the B2 cohort participants achieved >5% body weight reduction.
THDBH120Phase 2PeptideGLP-1/GIP receptor (dual)Weak signalFeatured results are safety only in this race
TifeglipronPhase 2Small moleculeGLP-1 receptorPartial signalFeatured results are safety only in this race
TisolagilinePhase 2Small moleculeMAO-Bnot yet gradedNo reviewed efficacy summary in this indication
TrevogrumabPhase 2Monoclonal antibodyMyostatin (GDF8)not yet gradedNo reviewed efficacy summary in this indication
UtreglutidePhase 2PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ZabopegdutidePhase 2PeptideGLP-1/glucagon receptor (dual)Partial signalFeatured results are safety only in this race
ZT006Phase 2PeptideGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
ARO-ALK7Phase 1/2RNA / oligonucleotideALK7 (Activin receptor-like kinase 7)not yet gradedNo reviewed efficacy summary in this indication
ARO-INHBEPhase 1/2RNA / oligonucleotideINHBE (Inhibin beta E chain / Activin E)not yet gradedNo reviewed efficacy summary in this indication
GUB-UCN2Phase 1/2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
MET-233iPhase 1/2PeptideAmylin receptorWeak signalNo reviewed efficacy summary in this indication
PB-718Phase 1/2PeptideGLP-1/glucagon receptor (dual)Weak signalNo reviewed efficacy summary in this indication
BMF-650Phase 1Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
DehydraTECH-CBD / SemaglutidePhase 1CombinationOral peptide delivery platform, GLP-1 receptorWeak signalFeatured results are safety only in this race
IBI3032Phase 1Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Liraglutide (HUC2-676)Phase 1PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PF-08642534Phase 1UndisclosedGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PF-08656795Phase 1UndisclosedGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (DWRX5003)Phase 1PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 95 furthest-along competitors are listed; 25 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Foundayo (orforglipron) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (9)
February 2027 (1)
Phase 3ObesityRecruiting
Est. primary completion 2027-02 · NCT06672549 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2027-05 · NCT07613307 · CT.gov ↗
What to watch
August 2027 (3)
Phase 3Type 2 DiabetesActive not recruiting
Est. primary completion 2027-08 · NCT06972472 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2027-08 · NCT06972459 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesActive not recruiting
Est. primary completion 2027-08 · NCT06993792 · CT.gov ↗
What to watch
September 2027 (3)
Phase 3HypertensionActive not recruiting
Est. primary completion 2027-09 · NCT06948435 · CT.gov ↗
What to watch
Phase 3HypertensionActive not recruiting
Est. primary completion 2027-09 · NCT06948422 · CT.gov ↗
What to watch
Phase 3HypertensionActive not recruiting
Est. primary completion 2027-09 · NCT06952530 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3ObesityRecruiting
Est. primary completion 2027-12 · NCT06672939 · CT.gov ↗
What to watch
2028 (4)
March 2028 (2)
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-03 · NCT07790861 · CT.gov ↗
What to watch
Phase 3ObesityRecruiting
Est. primary completion 2028-03 · NCT07202884 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3ObesityActive not recruiting
Est. primary completion 2028-04 · NCT07153471 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2028-06 · NCT07223593 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Phase 3HypertensionRecruiting
Est. primary completion 2029-08 · NCT07794579 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2029-09-30 · NCT07739537 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2030-03 · NCT07668336 · CT.gov ↗
What to watch
2031 (2)
July 2031 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2031-07-31 · NCT07729332 · CT.gov ↗
What to watch
August 2031 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2031-08 · NCT07241390 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 April 2026ApprovalFDA approves Foundayo (orforglipron) for weight management
US, FDA · Source ↗
1 April 2026ApprovalFDA Boxed Warning on Foundayo (NDA220934)
US, FDA · FDA · Source ↗
18 December 2025Topline resultATTAIN-MAINTAIN: orforglipron met primary endpoint
Eli Lilly · Source ↗
21 June 2025Topline resultACHIEVE-1 Phase 3 detailed results published in NEJM